Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP

ConditionChildhood ALL

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeUp to 18

SponsorFrench Africa Pediatric Oncology Group

About this trial

The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

French Africa Pediatric Oncology Group

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborator

Source ClinicalTrials.gov